跳转至内容
Merck
CN

D7285

3′-Deoxyguanosine

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C10H13N5O4
化学文摘社编号:
分子量:
267.24
UNSPSC Code:
41106305
PubChem Substance ID:
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


biological source

synthetic (organic)

assay

≥98% (HPLC)

form

powder

solubility

1 M NH4OH: 50 mg/mL, clear, colorless

SMILES string

NC1=NC(=O)c2ncn(C3OC(CO)CC3O)c2N1

InChI

1S/C10H13N5O4/c11-10-13-7-6(8(18)14-10)12-3-15(7)9-5(17)1-4(2-16)19-9/h3-5,9,16-17H,1-2H2,(H3,11,13,14,18)

InChI key

OROIAVZITJBGSM-UHFFFAOYSA-N

Application

3′-Deoxyguanosine (3dG) is used as a complexing ligand for enzymes, such as purine nucleoside phosphorylase (PNP), and receptors, such as G-coupled receptors, to enable structure analysis. 3′-Deoxyguanosine may be used to selectively impair transcription but not polyadenylation.


存储类别

13 - Non Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

新产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Ugo Traversa et al.
Bioorganic & medicinal chemistry, 11(24), 5417-5425 (2003-12-04)
Rat brain guanosine binding sites were studied by (i). a pharmacological approach to confirm the hypothesis of the existence of specific G-coupled receptors for guanosine (1) and, for the first time, delineate a structure-activity relationship for a series of guanosine
Juan M Traverso et al.
Molecular reproduction and development, 71(1), 107-114 (2005-03-01)
The control of protein synthesis during maturation in oocytes is mainly exerted through cytoplasmic polyadenylation of stored mRNAs. We first analyzed the polyadenylation status of cyclins A2 and B1 during in vitro maturation (IVM) of bovine oocytes, using Rapid Amplification
Robert W King et al.
Antiviral chemistry & chemotherapy, 13(6), 363-370 (2003-04-30)
The development of low molecular weight inhibitors of hepatitis C virus (HCV) replication has been hindered by the lack of a good cell-based system that models the entire HCV replication cycle. To date the only two therapies approved for the